Literature DB >> 3917257

Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.

A Beyer-Mears, E Cruz.   

Abstract

Aldose reductase is implicated in the pathogenesis of diabetic cataracts; therefore, inhibition of this enzyme subsequent to cataractogenesis may represent a therapeutic approach for restoration of lens physiology. In the present study, the effect of aldose reductase inhibition subsequent to stage I cataract formation was investigated in the streptozocin-induced diabetic rat. Our results indicated that the aldose reductase inhibitor sorbinil, a spirohydantoin, arrested further progression and promoted a reparative process despite continuation of hyperglycemia and elevated lens glucose. Quantitative analysis of scanning electron micrographs indicated that the afflicted lens regions were contained and their cellular components stabilized with regard to fiber hydration and interdigitation. The reparative process included: normalization of lens sorbitol, gradual recovery of existing fiber contour and interdigitation, production of new fibers, and partial restoration of lens myo-inositol content.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917257     DOI: 10.2337/diab.34.1.15

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

Review 1.  Aldose reductase inhibitors and late complications of diabetes.

Authors:  P Benfield
Journal:  Drugs       Date:  1986       Impact factor: 9.546

2.  Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats.

Authors:  P B Inskeep; A E Reed; R A Ronfeld
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

3.  A novel polycyclic meroterpenoid with aldose reductase inhibitory activity from medicinal mushroom Ganoderma leucocontextum.

Authors:  Jinjin Zhang; Ke Ma; Hongyu Chen; Kai Wang; Weiping Xiong; Li Bao; Hongwei Liu
Journal:  J Antibiot (Tokyo)       Date:  2017-05-24       Impact factor: 2.649

4.  The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats.

Authors:  D J Otter; R Chess-Williams
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

5.  Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells.

Authors:  Kaori Yama; Keisuke Sato; Natsuki Abe; Yu Murao; Ryosuke Tatsunami; Yoshiko Tampo
Journal:  Redox Biol       Date:  2014-12-10       Impact factor: 11.799

6.  Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation.

Authors:  Keisuke Sato; Kaori Yama; Yu Murao; Ryosuke Tatsunami; Yoshiko Tampo
Journal:  Redox Biol       Date:  2013-11-19       Impact factor: 11.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.